Drugs / NTRA-2112
NTRA-2112
English name recombinant human insulin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02510560 | Oct 2016 → Apr 2018 | malabsorption syndrome | Elgan Pharma Ltd. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NTRA-2112 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02510560 ↗ |
| Modality | Protein / enzyme biologic | “Efficacy and Safety of Enteral Recombinant Human Insulin in Preterm Infants: A Randomized Clinical Trial.” PMID 35226099 ↗ May 2022 |
| Route | Oral | “To be administered orally with daily feed for 28 days or until discharge from hospital.” NCT02510560 ↗ |